Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Sulfonylurea (SU) Monotherapy: A CANVAS Substudy

被引：0

|

作者：

Fulcher, Greg

Matthews, David

Perkovic, Vlado

Mahaffey, Kenneth W.

Weiss, Robert

Rosenstock, Julio

Capuano, George

Desai, Mehul

Shaw, Wayne

Vercruysse, Frank

Meininger, Gary

Neal, Bruce

机构：

来源：

DIABETES | 2013年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1124-P

引用

收藏

页码：A292 / A292

页数：1

相关论文

共 50 条

[1] Efficacy and Safety of Canagliflozin (CANA) Monotherapy in Subjects With Type 2 Diabetes Mellitus (T2DM) Over 52 Weeks
Stenloef, Kaj
Cefalu, William T.
Kim, Kyoung-Ah
Jodar, Esteban
Alba, Maria
Edwards, Robert
Tong, Cindy
Canovatchel, William
Meininger, Gary
DIABETES, 2013, 62 : A303 - A303
[2] Genital Mycotic Infections With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
Nyirjesy, Paul
Sobel, Jack
Fung, Albert
Gassmann-Mayer, Cristiana
Ways, Kirk
Usiskin, Keith
DIABETES, 2013, 62 : A276 - A276
[3] Urinary Tract Infection (UTI) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
Nicolle, Lindsay E.
Capuano, George
Fung, Albert
Usiskin, Keith
DIABETES, 2013, 62 : A296 - A296
[4] Lower Blood Pressure (BP) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
Weir, Matthew R.
Januszewicz, Andrzej
Gilbert, Richard
Gonzalez, Fernando Lavalle
Meininger, Gary
DIABETES, 2013, 62 : A278 - A278
[5] Efficacy and Safety of Canagliflozin (CANA) in Japanese Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Diet and Exercise over 24 Weeks
Inagaki, Nobuya
Kondo, Kazuoki
Yoshinari, Toru
Maruyama, Nobuko
Takahashi, Nahoko
Susuta, Yutaka
Kuki, Hideki
DIABETES, 2014, 63 : A266 - A266
[6] Blood Pressure (BP) Effects of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Pfeifer, Michael
Townsend, Raymond
Davies, Michael J.
Vijapurkar, Ujjwala
Ren, Jimmy
DIABETES, 2016, 65 : A303 - A303
[7] Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
Stenlof, K.
Cefalu, W. T.
Kim, K. -A.
Alba, M.
Usiskin, K.
Tong, C.
Canovatchel, W.
Meininger, G.
DIABETES OBESITY & METABOLISM, 2013, 15 (04): : 372 - 382
[8] Achievement of Diabetes-related Treatment Goals with Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Blonde, Lawrence
Woo, Vincent
Mathieu, Chantal
Yee, Jacqueline
Vijapurkar, Ujjwala
Meininger, Gary
DIABETES, 2014, 63 : A284 - A284
[9] Effect of Canagliflozin (CANA) on Liver Function Tests (LFTs) in Patients with Type 2 Diabetes Mellitus (T2DM)
Usiskin, Keith
Leiter, Lawrence A.
Forst, Thomas
Polidori, David
Xie, John
Sha, Sue
DIABETES, 2014, 63 : A284 - A284
[10] Pharmacokinetics (PK) and Pharmacodynamics (PD) of Canagliflozin (CANA) in Pediatric Patients with Type 2 Diabetes Mellitus (T2DM)
Tamborlane, William
Polidori, David
Di Prospero, Nicolas
DIABETES, 2017, 66 : A371 - A371

← 1 2 3 4 5 →